Richard E. Lowenthal
CIK: 0001378550
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ARS Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (27 total)
- Jan 2, 2026SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
875K shares- - Jan 2, 2026SPRY
ARS Pharmaceuticals, Inc.
Award(A)IndirectStock Option (right to buy)
240K shares- - Aug 21, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $14.49$724K - Jan 2, 2025SPRY
ARS Pharmaceuticals, Inc.
Award(A)IndirectStock Option (right to buy)
261.9K shares- - Jan 2, 2025SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
767.6K shares- - Dec 17, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $11.67$584K - Dec 17, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $11.67$584K - Dec 10, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $13.17$658K - Dec 10, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $13.16$658K - Dec 6, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Indirect13.8K shares at avg. $1.44$20K - Dec 6, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Indirect11.9K shares at avg. $8.42$100K - Dec 6, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct11.9K shares at avg. $8.42$100K - Nov 19, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $13.95$698K - Nov 19, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $13.95$697K - Nov 12, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect45K shares at avg. $16.76$755K - Nov 12, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect5K shares at avg. $17.64$87K - Nov 12, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect45.1K shares at avg. $16.76$756K - Nov 12, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect4.9K shares at avg. $17.64$86K - Oct 15, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect48.6K shares at avg. $14.86$722K - Oct 15, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect1.5K shares at avg. $15.25$22K - Oct 15, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $14.88$744K - Oct 8, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $13.83$691K - Oct 8, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $13.83$691K - Sep 17, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $12.93$647K - Sep 17, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Indirect50K shares at avg. $12.93$647K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 875,000 | - | - | Direct |
| Jan 2, 2026 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 240,000 | - | - | Indirect |
| Aug 21, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $14.49 | $724,345 | Indirect |
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 261,900 | - | - | Indirect |
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 767,600 | - | - | Direct |
| Dec 17, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $11.67 | $583,525 | Indirect |
| Dec 17, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $11.67 | $583,575 | Indirect |
| Dec 10, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $13.17 | $658,265 | Indirect |
| Dec 10, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $13.16 | $658,155 | Indirect |
| Dec 6, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 13,789 | $1.44 | $19,856 | Indirect |
| Dec 6, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 11,876 | $8.42 | $99,996 | Indirect |
| Dec 6, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 11,876 | $8.42 | $99,996 | Direct |
| Nov 19, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $13.95 | $697,510 | Indirect |
| Nov 19, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $13.95 | $697,450 | Indirect |
| Nov 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 45,045 | $16.76 | $754,905 | Indirect |
| Nov 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 4,955 | $17.64 | $87,421 | Indirect |
| Nov 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 45,124 | $16.76 | $756,296 | Indirect |
| Nov 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 4,876 | $17.64 | $86,020 | Indirect |
| Oct 15, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 48,550 | $14.86 | $721,657 | Indirect |
| Oct 15, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 1,450 | $15.25 | $22,118 | Indirect |
| Oct 15, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $14.88 | $743,820 | Indirect |
| Oct 8, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $13.83 | $691,390 | Indirect |
| Oct 8, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $13.83 | $691,385 | Indirect |
| Sep 17, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $12.93 | $646,680 | Indirect |
| Sep 17, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $12.93 | $646,525 | Indirect |
1-25 of 27 transactions
About Lowenthal Richard E
Lowenthal Richard E (SEC CIK 0001378550) files insider reports with the SEC as PRESIDENT AND CEO of ARS Pharmaceuticals, Inc. (SPRY).
Signal8 holds 12 ownership filings by Lowenthal Richard E, all Form 4s, filed between Sep 12, 2024 and Jan 5, 2026. Those filings report 27 transactions, from Sep 10, 2024 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lowenthal Richard E's filings is in SAN DIEGO, CA.
Recent filings by Lowenthal Richard E
- Jan 2, 2026: Grants or awards of SPRY derivative securities (2 lines, Form 4, code A).
- Aug 21, 2025: Open-market sale of SPRY shares (Form 4, code S).
- Jan 2, 2025: Grants or awards of SPRY derivative securities (2 lines, Form 4, code A).
- Dec 17, 2024: Open-market sales of SPRY shares (2 lines, Form 4, code S).
- Dec 10, 2024: Open-market sales of SPRY shares (2 lines, Form 4, code S).
Other insiders filing for ARS Pharmaceuticals, Inc. (SPRY)
- Casale Donn, President and CEO
- Smith Margaret Ekins, Chief Commercial Officer
- RA CAPITAL MANAGEMENT, L.P., Director
- Dadoo Rajeev, Director
- Shah Pratik, Director
- Kelly Michael, Director